Business Insider

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020 ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the ...
MedPage Today

Oral Microbiome Therapy Tied to Low Recurrence of C. Diff

A potential first-in-class investigational microbiome therapeutic, SER-109, was safe and observed to sustain low Clostridioides difficile (C. diff) recurrence rates for adults, according to the phase ...
Nasdaq

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...
Healthline

What to Know About C. Diff (Clostridioides Difficile) Infection Recurrence

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...
Nasdaq

Pfizer : Phase 3 Trial Of Investigational C. Difficile Vaccine Fails To Meet Primary Goal

(RTTNews) - Pfizer Inc. (PFE) said Tuesday that the CLOVER trial, a pivotal Phase 3 study evaluating its Clostridioides difficile vaccine candidate (PF-06425090) in the prevention of C. difficile ...